In short. Volume, longevity and any claim that the material behaves like a filler or like a scaffold graft rather than a structure.
Key points
- A graft is living tissue that becomes part of the tissue it is placed in.
- A fibrin network is a protein structure that is broken down and cleared.
- Both can be called scaffolds in different contexts, and only one of them is what is injected here.
Claims about this preparation fail in a consistent way: each takes something the material genuinely is and extends it into something the material does not do. Listing them makes the boundary visible.
That it restores volume
A filler is a defined volume of a material that holds the space it occupies and is not quickly broken down. A fibrin preparation is reabsorbed over a short period. Volume that is reabsorbed cannot restore volume in the sense that word carries in aesthetic practice, and a person who has been led to expect a lasting change in shape has been misled about the material rather than merely disappointed by the result.
That a scaffold means tissue is rebuilt
A fibrin network is a structure, and describing it as a scaffold is a fair description of the material. Whether the surrounding tissue uses that structure to rebuild anything, and whether the rebuilding produces a visible change, are the questions that remain open. The word scaffold does a great deal of work in this subject and it is doing it by analogy with materials that are not this one.
A structure is not a graft
A graft is living tissue that becomes part of the tissue it is placed in. A fibrin network is a protein structure that is broken down and cleared. Both can be called scaffolds in different contexts, and only one of them is what is injected here.
That the effect lasts
Because the material does not persist, any effect that outlasts it has to be explained by the response it provoked rather than by its presence. That explanation is the mechanism story, and it has not been demonstrated in a comparison against an alternative. A claim of a lasting result is therefore a claim about an unproven mechanism rather than a claim about a material that is still there.
That being your own blood removes the risks
Autologous material removes the risk of transmitting an infection from a donor and the risk of an immune reaction to a foreign substance. Those are two specific risks and removing them is genuinely valuable. It does not remove the risk of infection introduced during preparation, which is the recognised risk of a point-of-care biologic, and it does not remove bruising, swelling, discomfort or an unsatisfactory result.
That preparation is comparable between clinics
No common standard exists for the tube, the device, the spin or the interval before use. Two clinics describing the same treatment may be injecting preparations that differ in composition, and a claim that the treatment works is a claim about a material that has not been defined.
Three claims that do not hold
- It restores volume — when the material is reabsorbed and a filler is not.
- It is a scaffold graft — when a fibrin network is a structure rather than living tissue.
- Your own blood makes it safe — when preparation introduces a risk that the source of the blood does not address.
Refusing these claims leaves the established findings — the preparation, the fibrin network, the laboratory measurement, the removal of two specific risks — standing where they belong.
Frequently asked questions
Does PRF add volume?
Not in the way a filler does. A filler is a defined volume that stays where it is placed and holds the space it occupies. This preparation is reabsorbed over a short period, so any volume it provides is temporary and it cannot restore volume in the sense the word is used for a filler.
Is a fibrin scaffold the same as a tissue graft?
No. A network of fibrin is a structure, and describing it as a scaffold is an accurate description of the material. A graft is living tissue that becomes part of what it is placed in. The two are different objects and the second is not what is being injected.
Is being autologous a safety guarantee?
It is not. Using the patient's own blood removes the risk of donor transmission and of an immune reaction to a foreign substance. It does not remove the risk of infection introduced during preparation, nor bruising, swelling or an unsatisfactory result.
Risks & Limitations
- The preparation is made in the room and is not standardised, so two clinics offering the same named treatment are not necessarily offering the same material.
- Blood handled outside a controlled laboratory is a medium in which bacteria grow, so preparation carries a risk of infection that the source of the blood does not remove.
- The material is reabsorbed over a short period, so it does not restore volume the way a filler does.
- There is no product authorisation and no approved indication, because there is no manufactured product to authorise.
- Growth factors measured in laboratory work are a finding about the material and not a demonstrated clinical result.
When to Seek Care
- Redness, warmth, swelling or pain that is increasing rather than settling after an injection.
- Discharge from an injection site, or a fever — seek prompt clinical assessment.
- An uneven or lumpy result, or any change in the treated area that concerns you.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — guidance on autologous cellular products and point-of-care preparation
- European Medicines Agency (EMA) and national regulators — guidance on blood-derived and autologous treatments
- National Medical Products Administration (NMPA, China) — regulation of blood-derived preparations and devices
- World Health Organization (WHO) — guidance on the safe preparation and handling of blood components
- Cochrane Library — systematic reviews of platelet concentrates for skin and wound indications
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.